{
  "Country": "DE",
  "PICOs": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel (only for patients with PD-L1 negative tumours)",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pemetrexed (only for patients with PD-L1 negative tumours and except in cases predominantly squamous histology)",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Nivolumab",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Pembrolizumab (only for patients with PD-L1 expressing tumours (PD-L1 expr â‰¥ 1% of tumour cells))",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Atezolizumab",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with cytotoxic chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumours and adenocarcinoma histology)",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Afatinib",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Erlotinib",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    },
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation after first-line therapy with an anti-PD-1/PD-L1 in combination with platinum-containing chemotherapy",
      "Intervention": "New medicine under assessment",
      "Comparator": "Vinorelbine",
      "Outcomes": "Mortality, morbidity, health-related quality of life, and side effects"
    }
  ]
}